CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Patterns of use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-Retrospective AMI Study Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection BMI, Infarct Size, and Clinical Outcomes Following Primary PCI Patient-Level Analysis From 6 Randomized Trials

Original ResearchVolume 72, Issue 25, December 2018

JOURNAL:J Am Coll Cardiol. Article Link

Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring

JD Mitchell, N Fergestrom, BF Gage et al. Keywords: atherosclerotic cardiovascular disease; calcium score; cardiovascular risk; primary prevention; screening

ABSTRACT


BACKGROUND - Compared with traditional risk factors, coronary artery calcium (CAC) scores improve prognostic accuracy for atherosclerotic cardiovascular disease (ASCVD) outcomes. However, the relative impact of statins on ASCVD outcomes stratified by CAC scores is unknown.

 

OBJECTIVES -  The authors sought to determine whether CAC can identify patients most likely to benefit from statin treatment.

 

METHODS - The authors identified consecutive subjects without pre-existing ASCVD or malignancy who underwent CAC scoring from 2002 to 2009 at Walter Reed Army Medical Center. The primary outcome was first major adverse cardiovascular event (MACE), a composite of acute myocardial infarction, stroke, and cardiovascular death. The effect of statin therapy on outcomes was analyzed stratified by CAC presence and severity, after adjusting for baseline comorbidities with inverse probability of treatment weights based on propensity scores.

 

RESULTS -  A total of 13,644 patients (mean age 50 years; 71% men) were followed for a median of 9.4 years. Comparing patients with and without statin exposure, statin therapy was associated with reduced risk of MACE in patients with CAC (adjusted subhazard ratio: 0.76; 95% confidence interval: 0.60 to 0.95; p = 0.015), but not in patients without CAC (adjusted subhazard ratio: 1.00; 95% confidence interval: 0.79 to 1.27; p = 0.99). The effect of statin use on MACE was significantly related to the severity of CAC (p < 0.0001 for interaction), with the number needed to treat to prevent 1 initial MACE outcome over 10 years ranging from 100 (CAC 1 to 100) to 12 (CAC >100).

 

CONCLUSIONS -  In a largescale cohort without baseline ASCVD, the presence and severity of CAC identified patients most likely to benefit from statins for the primary prevention of cardiovascular diseases.